iRadimed (NASDAQ:IRMD) Shares Cross Below 200 Day Moving Average - Time to Sell?

Key Points

• iRadimed shares fell below their 200-day moving average, trading as low as $85.57 versus the $94.77 average and last changing hands at $88.02.
• Analyst sentiment remains positive but has weakened, with two ratings downgraded to “Hold.” The consensus rating is “Moderate Buy,” with a target price of $120.
• The company exceeded quarterly earnings and revenue estimates, while declaring a quarterly dividend of $0.20, equivalent to an annualized yield of 0.9%.

iRadimed Corporation (NASDAQ:IRMD - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $94.77 and traded as low as $85.57. iRadimed shares last traded at $88.02, with a volume of 106,372 shares.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Wall Street Zen cut shares of iRadimed from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings cut iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $120.00.

iRadimed Stock Up 1.2%

The firm's fifty day simple moving average is $94.04 and its 200-day simple moving average is $94.77. The company has a market cap of $1.13 billion, a PE ratio of 49.17 and a beta of 0.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The business had revenue of $20.47 million during the quarter, compared to analysts' expectations of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts predict that iRadimed Corporation will post 1.98 earnings per share for the current year.

iRadimed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 14th. iRadimed's payout ratio is 44.69%.

Insider Activity

In related news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the sale, the chief executive officer owned 2,162,500 shares of the company's stock, valued at $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 34.60% of the stock is owned by corporate insiders.

Institutional Trading of iRadimed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Punch & Associates Investment Management Inc. purchased a new position in iRadimed in the 2nd quarter valued at about $1,911,000. Bank of America Corp DE acquired a new stake in shares of iRadimed during the 2nd quarter worth about $1,834,000. Man Group plc purchased a new stake in shares of iRadimed during the second quarter worth about $1,514,000. Jupiter Topco LLC purchased a new stake in shares of iRadimed during the second quarter worth about $296,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of iRadimed during the second quarter worth about $1,130,000. Hedge funds and other institutional investors own 92.34% of the company's stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source